Treatment of co-morbid mental illness in primary care: How to minimize weight gain, diabetes, and metabolic syndrome

International Journal of Psychiatry in Medicine

Volumn 41, Issue 2, 2011, Pages 127-142

  Gibson, Maria ^a,b   Carek, Peter J ^a   Sullivan, Brigid ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b NONE   (United States)

Author keywords

diabetes; mental illness; metabolic risk; metabolic syndrome; obesity

Indexed keywords

ARIPIPRAZOLE; CITALOPRAM; CLOZAPINE; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; GLUCOSE; LIPID; LITHIUM; LUVOC; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VALPROATE SEMISODIUM; ZIPRASIDONE;

ABDOMINAL OBESITY; ARTICLE; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; COMORBIDITY; DIABETES MELLITUS; DYSLIPIDEMIA; HUMAN; HYPERLIPIDEMIA; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; MENTAL DISEASE; METABOLIC SYNDROME X; OBESITY; PATIENT MONITORING; PRIMARY MEDICAL CARE; SIDE EFFECT; WAIST CIRCUMFERENCE; WEIGHT GAIN;

COMORBIDITY; DIABETES MELLITUS, TYPE 2; HEALTH PROMOTION; HUMANS; LIFE STYLE; MENTAL DISORDERS; METABOLIC SYNDROME X; PRIMARY HEALTH CARE; RISK FACTORS; WEIGHT GAIN;

EID: 79955121717     PISSN: 00912174     EISSN: 15413527     Source Type: Journal    
DOI: 10.2190/PM.41.2.c     Document Type: Article

References (64)

1. Fleischhacker WW, Cetkovich-Bakmas M, De Hert M, Hennekens C, Lambert M, Leucht S, et al. Comorbid somatic illnesses in patients with severe mental disorders: Clinical, policy and research challenges. Journal of Clinical Psychiatry 2008;69: 514-519. (Pubitemid 351792324)
2. Casey DE. Metabolic issues and cardiovascular disease in patients with psychiatric disorders. American Journal of Medicine 2005;188(Suppl 2):15S-22S.
3. Miller BJ, Paschall CB 3rd, Svendsen DP. Mortality and medical comorbidity among patients with serious mental illness. Psychiatric Services 2006;57:1482-1487. (Pubitemid 44671660)
4. Susce MT, Villanueva N, Diaz FJ, de Leon J. Obesity and associated complications in patients with severe mental illnesses: A cross-sectional survey. Journal of Clinical Psychiatry 2005;66:167-173.
5. Jones DR, Macias C, Barreira PJ, Fisher WH, Hargreaves WA, Harding CM. Prevalence, severity, and co-occurrence of chronic physical health problems of persons with serious mental illness. Psychiatric Services 2004;55:1250-1257. (Pubitemid 39441587)
6. Heiskanen T, Niskanen L, Lyytikainen R, et al. Metabolic syndrome in patients with schizophrenia. Journal of Clinical Psychiatry 2003;64:575-579. (Pubitemid 36618288)
7. Heiskanen TH, Niskanen LK, Hintikka JJ, Koivumaa-Honkanen HT, Honkalampi KM, Haatainen KM, Viinamäki HT. Metabolic syndrome and depression: A crosssectional analysis. Journal of Clinical Psychiatry 2006;67(9):1422-1427. (Pubitemid 44583390)
8. Fagiolini A, Frank E, Scott JA, Turkin S, Kupfer DJ. Metabolic syndrome in bipolar disorder: Findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disorders 2005;7(5):424-430. (Pubitemid 41419409)
9. Goff DC, Cather C, Evins AE, et al. Medical morbidity and mortality in schizophrenia: Guidelines for psychiatrists. Journal of Clinical Psychiatry 2005;66(2):183-194.
10. Guo JJ, Keck PE Jr, Corey-Lisle PK, et al. Risk of diabetes mellitus associated with atypical antipsychotic use among Medicaid patients with bipolar disorder: A nested case-control study. Pharmacotherapy 2007;27(1):27-35. (Pubitemid 46067960)
11. American Diabetes Association: Consensus development conference on antipsychotic drugs and obesity and diabetes (Consensus Statement). Diabetes Care 2004;27: 596-601.
12. Das-Munshi J, Stewart R, Ismail K, Bebbington PE, Jenkins R, Prince MJ. Diabetes, common mental disorders, and disability: Findings from the UK national psychiatry morbidity survey. Psychosomatic Medicine 2007;69:543-550. (Pubitemid 47205738)
13. McKellar JD, Humphreys K, Piette JD. Depression increases diabetes symptoms by complicating patients' self-care adherence. Diabetes Education 2004;30: 485-492. (Pubitemid 38843923)
14. Kiraly B, Gunning K, Leiser J. Primary care issues in patients with mental illness. American Family Physician 2008;78:355-362.
15. Crimson ML, Argo TR, Buckley PF. Schizophrenia. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors, Pharmacotherapy: A pathophysiologic approach (7th ed.). New York: McGraw-Hill, 2008:1099-1139.
16. Stahl SM, Mignon L, Meyer JM. Which comes first: Atypical antipsychotic or cardiometabolic risk? Acta Psychiatrica Scandinavica 2009;119:171-179.
17. Newcomer JW. Metabolic considerations in the use of antipsychotic medications. Journal of Clinical Psychiatry 2007;68(suppl 1):20-27.
18. Alvarez-Jiménez M, González-Blanch C, Vázquez- Barquero JL, Pérez I. Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: A randomized controlled trial. Journal of Clinical Psychiatry 2006;67(8):1253-1260: s.n.
19. Allison DB, Mentore JL, Heo M, Chandler LP, Capelleri JC, Infante MC, et al. Antipsychotic induced weight gain: Comprehensive research synthesis. American Journal of Psychiatry 1999;156:1686-1696. (Pubitemid 29517559)
20. Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003;28:519-526: s.n.
21. Muench J, Hamer AM. Adverse effects of antipsychotic medications. American Family Physician 2010;81(5):617-622.
22. Ramaswamy K, Kozma CM, Nasrallah H. Risk of diabetic ketoacidosis after exposure to risperidone or olanzapine. Drug Safety 2007;30(7):589-599. (Pubitemid 47037318)
23. Raeder MB, Bjelland I, Vollset SE, Steen VM. Obesity, dyslipidemia, and diabetes with selective serotonin reuptake inhibitors: The Hordaland health study. Journal of Clinical Psychiatry 2006;67(12):1974-1982. (Pubitemid 46048196)
24. Maina G, Albert U, Salvi V, Bogetto F. Weight gain during long-term treatment of obsessive-compulsive disorder: A prospective comparison between serotonin reuptake inhibitors. Journal of Clinical Psychiatry 2004;65(10):1365-1371.
25. Fava M. Weight gain and antidepressants. Journal of Clinical Psychiatry 2000; 61(Suppl 11):37-41. (Pubitemid 30616693)
26. Van Reedt Dortland AK, Giltay E, Van Veen T, Zitman FG, Penninx BW. Metabolic syndrome abnormalities are associated with severity of anxiety and depression and with tricyclic antidepressant use. Acta Psychiatrica Scandinavica 2010; 122:30-39.
27. Martin CK, Han H, Anton SD, Greenway FL, Smith SR. Effect of valproic acid on body weight, food intake, physical activity and hormones: Results of a randomized controlled trial. Journal of Psychopharmacology 2009;23(7):814-825.
28. Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, Petty F, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with 2-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Archives of General Psychiatry 2000;57:481-489. (Pubitemid 30257262)
29. Sachs G, Bowden C, Calabrese JR, Ketter T, Thompson T, White R, Bentley B. Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder. Bipolar Disorder 2006;8:175-181. (Pubitemid 44026770)
30. DeToledo JC, Toledo C, DeCerce J, Ramsay RE. Changes in body weight with chronic, high-dose gabapentin therapy. Therapy Drug Monitoring 1997;19:394-396. (Pubitemid 28074034)
31. Hogan RE, Bertrand ME, Deaton RL, Sommerville KW. Total percentage body weight changes during add-on therapy with tiagabine, carbamazepine and phenytoin. Epilepsy Research 2000;41:23-28. (Pubitemid 30621398)
32. Devinsky O, Vuong A, Hammer A, Barrett PS. Stable weight during lamotrigine therapy: A review of 32 studies. Neurology 2000;54:973-975. (Pubitemid 30111362)
33. Henderson DC. Atypical antipsychotic-induced diabetes mellitus: How strong is the evidence? CNS Drugs 2002;16:77-89. (Pubitemid 34155205)
34. Lieberman JA. Metabolic changes associated with antipsychotic use Primary Care Companion. Journal of Clinical Psychiatry 2004;6(suppl 2):8-13.
35. American Dietetic Association. Adult weight management evidence based nutrition practice guidelines. Accessed September 18, 2010 from http://www.adaevidencelibrary.com
36. American college of sports medicine position stand. Appropriate intervention strategies for weight loss and prevention of weight regain for adults. Medical Science Sports and Exercise 2001;33:2145-2156.
37. Executive Summary: Standards of medical care in diabetes-2010. Diabetes Care 2010;33:S4-S10.
38. Third report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III. Accessed on October 28, 2010 from www.nhlbi.nih.gov/guidelines/cholesterol/index.htm
39. National Institutes of Health, National Heart, Lung and Blood Institute. North American Association for the Study of Obesity. The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. 2000. N 00-4084.
40. Svetkey LP, Stevens VJ, Brantley PJ, et al. Comparison of strategies for sustaining weight loss: The weight loss maintenance randomized controlled trial. Journal of the American Medical Association 2008;299:1139-1148. (Pubitemid 351398428)
41. Silverstein SM, Bellack AS. A scientific agenda for the concept of recovery as it applies to schizophrenia. Clinical Psychology Review 2008;28:1108-1124.
42. Compton MT, Daumit GL, Druss BG. Cigarette smoking and overweight/obesity among individuals with serious mental illnesses: A preventative perspective. Harvard Review of Psychiatry 2006;14:212-222. (Pubitemid 44260109)
43. Cabassa LJ, Ezell JM, Lewis-Fernández R. Lifestyle interventions for adults serious mental illness: A systematic literature review. Psychiatric Services 2010;61: 774-782.
44. Bushe CJ, Bradley AJ. Changes in weight and metabolic parameters during treatment with antipsychotics and metformin: do the data inform as to potential guideline development? A systematic review of clinical studies. International Journal of Clinical Practice 2009;63(12):1743-1761.
45. Wu RR, Zhao JP, Guo XF, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: A double-blind, placebo-controlled study. American Journal of Psychiatry 2008;165:352-358.
46. Baptista T, Martinez J, Lacruz A, et al. Metformin for prevention of weight gain and insulin resistance with olanzapine: A double-blind placebo-controlled trial. Canadian Journal of Psychiatry 2006;51:192-196.
47. Maddi S, Fox R, Harvey R, Lu J, Khoshaba DM, Persico M. Reduction in psychopathology following bariatric surgery for morbid obesity. Obesity Surgery 2001;(11): 680-685. (Pubitemid 34014520)
48. Ko YH, Joe SH, Jung IK, Kim SH. Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clinical Neuropharmacology 2005;28:169-175.
49. Buchwald H, Yoav A, Braunwald E, Jensen MD, Pories W, Fahrbach K, et al. Bariatric surgery: A systematic review and meta-analysis. Journal of the American Medical Association 2004;292:1724-1737. (Pubitemid 39346675)
50. Dixon JB, Dixon M, O'Brien PE. Pre-operative predictors of weight loss at 1-year after lap-band (R). Obesity Surgery 2001;11:200-207. (Pubitemid 33701862)
51. Lehman AF, Lieberman JA, Dixon LB, et al., for the American Psychiatric Association Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia (2nd ed.). American Journal of Psychiatry 2004; 161(2 Suppl):1-56.
52. Levinson Miller C, Druss BG, Dombrowski EA, Rosen-Heck RA. Barriers to primary medical care among patients at a community mental health center. Psychiatric Services 2003;54(8):1158-1160. (Pubitemid 36951519)
53. Chafetz L, White MC, Collins-Bride G, Nickens J, Cooper BA. Predictors of physical functioning among adults with severe mental illness. Psychiatric Services 2006;57(2): 225-231. (Pubitemid 43214469)
54. Horvitz-Lennon M, Kilbourne AM, Pincus HA. From silos to bridges: Meeting the general health care needs of adults with severe mental illnesses. Health Affairs 2006;25(3):659-669. (Pubitemid 43824915)
55. Druss BG, Von Esenwein SA, Compton MT, Rask KJ, Zhao L, Parker RMA. Randomized trial of medical care management for community mental health settings: The Primary Care Access, Referral, and Evaluation (PCARE) Study. American Journal of Psychiatry 2010;167:151-159.
56. Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: A critical overview. CMA Journal 2005;172(13):1703-1711. (Pubitemid 40896865)
57. Fava M, Judge R, Hoog SL, Nilsson ME, Koke SC. Fluoxetine versus sertraline and paroxetine in major depressive disorder: Changes in weight with long-term treatment. Journal of Clinical Psychiatry 2000;61(11):863-867.
58. Hochstrasser B, Isaksen PM, Koponen H, Lauritzen L, Mahnert FA, Rouillon F, et al. Weight gain during long-term treatment of obsessive-compulsive disorder: A prospective comparison between serotonin reuptake inhibitors. British Journal of Psychiatry 2001;178:304.
59. Centorrino F, Wurtman JJ, Duca KA, Fellman VH, Fogarty KV, Berry JM, et al. Weight loss in overweight patients maintained on atypical antipsychotic agents. International Journal of Obesity 2006;30:1011-1016. (Pubitemid 43801204)
60. Menza M, Vreeland B, Minsky S, et al. Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. Journal of Clinical Psychiatry 2004;65:471-477.
61. Brown C, Goetz J, Van Sciver A, et al. A psychiatric rehabilitation approach to weight loss. Psychiatric Rehabilitation Journal 2006;29:267-273.
62. Brar JS, Ganguli R, Pandina G, et al. Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. Journal of Clinical Psychiatry 2005;66:205-212. (Pubitemid 40314327)
63. Jean-Baptiste M, Tek C, Liskov E, et al. A pilot study of a weight management program with food provision in schizophrenia. Schizophrenia Research 2007;96: 198-205. (Pubitemid 47494625)
64. Van Citters AD, Pratt SI, Jue K, et al. A pilot evaluation of the In SHAPE individualized health promotion interventions for adults with mental illness. Community Mental Health Journal, December 10, 2009 [Epub ahead of print].